The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Myriad submits sPMA for myChoice CDx with Lynparza in first-line maintenance therapy in advanced ovarian cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Myriad Genetics has submitted a supplementary premarket approval application to FDA for its myChoice CDx test to help identify women with advanced ovarian cancer who are potential candidates for maintenance therapy with Lynparza (olaparib) in combination with bevacizumab.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

White House

RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, gender
One month in: Trump’s impact on oncology

Earlier this week, Robert F. Kennedy Jr. was confirmed as secretary of Health and Human Services amid many resignations at federal health agencies and cancellations of NIH and NCAB meetings. All of this happened at a time when the Trump administration is reportedly preparing to fire thousands of HHS workers.
By Claire Marie Porter and Jacquelyn Cobb
Sponsored

The War on Cancer: After half a century of progress, a promising prognosis may be Richard Nixon’s greatest legacy

Fifty-four years ago, in his State of the Union Message in January 1971, President Nixon proposed a visionary and vigorous new challenge.  He said “The time has come in America when the same kind of concentrated effort that split the atom and took man to the moon” should be applied to finding a cure for cancer.  He followed up by requesting an appropriation of $100 million, and the promise to ask for whatever additional funds could be effectively used.  
By Jim Byron
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account